Potential drug interaction between paclitaxel and clopidogrel.

about

Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study.

P2860

Q38726616-40AF9F56-6D33-4AD6-809B-08A2B222F6CD Q38948699-84719EAA-F362-4DC5-BCBC-861F4A1EFFC6

P2860

Potential drug interaction between paclitaxel and clopidogrel.

Item

http://www.wikidata.org/entity/Q42177423

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Potential drug interaction between paclitaxel and clopidogrel.

@en

Potential drug interaction between paclitaxel and clopidogrel.

@nl

type

Item

label

Potential drug interaction between paclitaxel and clopidogrel.

@en

Potential drug interaction between paclitaxel and clopidogrel.

@nl

prefLabel

Potential drug interaction between paclitaxel and clopidogrel.

@en

Potential drug interaction between paclitaxel and clopidogrel.

@nl

P1476

Potential drug interaction between paclitaxel and clopidogrel.

@en

P2093

Eiseki Usami

http://www.w3.org/2001/XMLSchema#string

Hiroki Asano

http://www.w3.org/2001/XMLSchema#string

Michio Kimura

http://www.w3.org/2001/XMLSchema#string

Tomoaki Yoshimura

http://www.w3.org/2001/XMLSchema#string

Yasutaka Shinoda

http://www.w3.org/2001/XMLSchema#string

P2860

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1.

Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma

CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel

CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.

Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer.

Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.

Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions

P304

141-145

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/BR.2016.685

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27347418

http://www.w3.org/2001/XMLSchema#string

P921

clopidogrel

P932

4906698

http://www.w3.org/2001/XMLSchema#string

Potential drug interaction between paclitaxel and clopidogrel.

about

P2860

P2860

Potential drug interaction between paclitaxel and clopidogrel.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932